Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Leukemia
Nilotinib Treatment May Cause Growth Deceleration in Children With Chronic Myelogenous Leukemia
Researchers sought to determine whether pediatric patients with CML may have attenuated growth when receiving treatment with nilotinib.
Study Identifies Factors Linked With CNS Relapse in Pediatric Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine the risk factors of CNS relapse in pediatric patients with ALL.
Poor Prognosis Seen for Patients With B-Cell Acute Lymphoblastic Leukemia Progression After CAR-T Therapy
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
Genetic Model Predicts Survival Outcome in Older Patients With AML Treated With Intensive Chemotherapy
Researchers sought to determine whether the ALFA decision tool would be able to determine the prognosis for older patients with AML treated with intensive chemotherapy.
CD70-Targeting CAR-T Cells Promising in Patients With Acute Myeloid Leukemia
Researchers sought to determine whether CD-70 targeting CAR-T therapy would be an effective therapeutic strategy in patients with AML.
Review of the Cardiovascular Risks of TKI Therapy for Chronic Myeloid Leukemia
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Chemotherapy With Antisense Oligonucleotide Oblimersen Improves Disease Free Survival in Older Patients With AML
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Technology-Based Psychosocial Program Effective for Adolescent Leukemia Survivors
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Tipifarnib May Yield Response in Chronic Myelomonocytic Leukemia or Other Myelodysplastic, Myeloproliferative Neoplasms
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
- Loading...
Loading...
Next post in ESMO 2021
Loading... 
Loading...